Teva Pharmaceutical Industries Limited reported impairment charges for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported impairment of long-lived assets of $68 million against $145 million. Intangible assets impairment was $61 million against $132 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.81 USD | +4.23% | +7.39% | +32.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.28% | 15.64B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- TEVA Stock
- News Teva Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023